importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma . Lancet 2001 ; 357 : 176 – 182 . 2 International Collaborative Ovarian Neoplasm Group . Paclitaxel plus carboplatin versus standard
Search Results
Metastatic Mucinous Ovarian Cancer and Treatment Decisions Based on Histology and Molecular Markers Rather Than the Primary Location
Angela Jain, Paula D. Ryan, and Michael V. Seiden
Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015
Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Michael Berry, Saundra S. Buys, Beth Crawford, Meagan Farmer, Susan Friedman, Judy E. Garber, Seema Khan, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer K. Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Huma Rana, Gwen Reiser, Mark E. Robson, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Myra J. Wick, Georgia L. Wiesner, Mary Dwyer, Rashmi Kumar, and Susan Darlow
cell ovarian cancers have also been reported in BRCA1/2 carriers. 10 – 15 Mutations are also associated with nonmucinous ovarian carcinoma as opposed to mucinous. 16 , 17 Mucinous epithelial ovarian carcinomas may be associated with other gene
Ovarian Cancer, Version 2.2013
Robert J. Morgan Jr, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Matthew A. Powell, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Julian C. Schink, Nelson Teng, Theresa L. Werner, Mary A. Dwyer, and Miranda Hughes
; 23 ( Suppl 10 ): x111 – 117 . 4. McCluggage WG . Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis . Pathology 2011 ; 43 : 420 – 432 . 5. Edge SB Byrd DR Compton CC
Epithelial Ovarian Cancer
Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner
the preferred treatment for recurrent ovarian carcinoma. However, some agents are preferred based on expert opinion (primarily because of decreased toxicity and/or marginally increased effectiveness; see page 97). A meta-analysis of 13 randomized
Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
Presented by: Joyce F. Liu
cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis . J Clin Oncol 2002 ; 120 : 1248 – 1259 . 5. Chang SJ , Bristow RE , Ryu HS . Impact of complete cytoreduction leaving no gross residual disease
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Featured Updates to the NCCN Guidelines
Deborah K. Armstrong, Ronald D. Alvarez, Floor J. Backes, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Viola C. Chitiyo, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Gary Leiserowitz, Joyce Liu, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac-Lima, Steven W. Remmenga, John Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsiros, Mary A. Dwyer, and Lisa Hang
JF , Touzet S , Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study . Ann Oncol 2005 ; 16 : 1795 – 1800 . 10.1093/annonc/mdi368 16093275 16
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Robert J. Morgan Jr, Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Kian Behbakht, Lee-may Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Sanja Percac-Lima, Mario Pineda, Steven C. Plaxe, Matthew A. Powell, Elena Ratner, Steven W. Remmenga, Peter G. Rose, Paul Sabbatini, Joseph T. Santoso, Theresa L. Werner, Jennifer Burns, and Miranda Hughes
invasive ovarian carcinoma, women with borderline epithelial tumors tend to be younger, are often diagnosed with stage I disease, and are candidates for fertility-sparing surgery. 235 , 236 Borderline epithelial tumors are rare tumors and are managed
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Joyce Liu, Haider Mahdi, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh
Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival . J Am Coll Surg 2015 ; 220 : 940 – 950 . 3. Ledermann JA , Raja FA , Fotopoulou C , . Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical
Next-Generation Sequencing: Role in Gynecologic Cancers
Tarra Evans and Ursula Matulonis
genomic and epigenomic signatures of human cancers, including gynecologic cancers. 7 In 2011, the TCGA Research Network published its results from the genomic evaluation of 489 high-grade serous ovarian carcinomas (HGSOCs) before treatment with systemic
Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer
Rajmohan Murali, Deborah F. Delair, Sarah M. Bean, Nadeem R. Abu-Rustum, and Robert A. Soslow
patients into prognostically distinct groups that may benefit from tailored treatment approaches. 52 Molecular Genetic Findings in Synchronous Endometrial and Ovarian Carcinomas The staging of patients with synchronous endometrial and ovarian
